Disclosures for "1,408 Patients Referred for Multiple Sclerosis (MS) Evaluation: Real World Clinical Characteristics Predictive of MS, and Prevalence of Symptoms Suggestive of Delayed Diagnosis"
-
Ms. Karpowicz has nothing to disclose.
-
Ms. Carvelli has nothing to disclose.
-
Ms. Houston has received personal compensation in the range of $500-$4,999 for serving as a Consultant for F. Hoffmann-La Roche Ltd.
-
Dr. Solomon has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for TG Therapeutics. Dr. Solomon has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Genentech/Roche . Dr. Solomon has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Kiniksa Pharmaceuticals . Dr. Solomon has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Bristol Myers Squibb. Dr. Solomon has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi. The institution of Dr. Solomon has received research support from Bristol Meyers Squibb.